Mr Lutnick has taken aim at Ireland's trade surplus, arguing it has come at the expense of the US. Meanwhile, his firm, Cantor Fitzgerald has a significant presence in Ireland, with offices in Cork, D

Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that

Cantor Fitzgerald analyst C J Muse maintained a Hold rating on Intel (INTC – Research Report) yesterday and set a price target of $22.00. The

“As you can imagine, the pain we suffered with Gary and 657 of my other friends and colleagues at Cantor Fitzgerald were killed on 9/11,” Lutnick said during his confirmation hearing before ...

This month, Flagstar offloaded $142 million of that portfolio, finding a buyer in Howard Lutnick’s Cantor Fitzgerald, PincusCo reported. A spokesperson for Cantor Fitzgerald did not return a ...

Cantor Fitzgerald currently has a “Overweight” rating and a $44.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.33) per share.

Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested

Cantor Fitzgerald reiterated a Neutral rating on Intel Corporation (NASDAQ:INTC) with a consistent price target of $22.00. According to InvestingPro analysis, Intel appears slightly undervalued at its current market cap of $86.

Cantor Fitzgerald analyst Sarah James maintained a Buy rating on Cigna (CI – Research Report) yesterday and set a price target of $350.00. The

Fintel reports that on January 30, 2025, Cantor Fitzgerald upgraded their outlook for Lam Research (NasdaqGS:LRCX) from Neutral to Overweight. Analyst Price Forecast Suggests 13.99% Upside As of January 28,

Cantor Fitzgerald LP’s lawsuit alleging a firm founded by four of its former investment bankers stole clients worth millions of dollars in profit was dismissed by a New York judge.

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. Analyst Price Forecast Suggests 87.91% Upside As of January 29,